$PPHM Peregrine Pharmaceuticals, announced there results from multiple new preclinical studies demonstrating enhanced anti-tumor activity and immune activation for combinations of a preclinical bavituximab equivalent and checkpoint inhibitors such as anti-PD-1 and anti-CTLA-4 in preclinical models of breast cancer and melanoma.

Read More: http://investorshangout.com/post/view?id=3324...z3r10eOcg4